The effects of acute tryptophan depletion on instrumental reward learning in anorexia nervosa – an fMRI study
Year: 2022
Type: article
Abstract: BACKGROUND: The serotonin (5-HT) hypothesis of anorexia nervosa (AN) posits that individuals predisposed toward or recovered from AN (recAN) have a central nervous hyperserotonergic state and therefore restrict food intake as a means to reduce 5-HT availability (via diminished tryptophan-derived precursor supply) and alleviate associated negative mood states. Importantly, the 5-HT system has also been generally implicated in reward processing, which has also been shown to be altered in AN. METHODS: In this double-blind crossover study, 22 individuals recAN and 25 healthy control participants (HC) underwent functional magnetic resonance imaging (fMRI) while performing an established instrumental reward learning paradigm during acute tryptophan depletion (ATD; a dietary intervention that lowers central nervous 5-HT availability) as well as a sham depletion. RESULTS: On a behavioral level, the main effects of reward and ATD were evident, but no group differences were found. fMRI analyses revealed a group × ATD × reward level interaction in the ventral anterior insula during reward anticipation as well as in the medial orbitofrontal cortex during reward consumption. DISCUSSION: The precise pattern of results is suggestive of a 'normalization' of reward-related neural responses during ATD in recAN compared to HC. Our results lend further evidence to the 5-HT hypothesis of AN. Decreasing central nervous 5-HT synthesis and availability during ATD and possibly also by dieting may be a means to normalize 5-HT availability and associated brain processes.
Source: Psychological Medicine
Authors: Julius Steding, Franziska Ritschel, Ilka Boehm, Daniel Geisler, Joseph A. King, Veit Roessner, Michael N. Smolka, Florian Daniel Zepf, Stefan Ehrlich
Language: English
Subfield: Clinical Psychology
Field: Psychology
Domain: Social Sciences
Open Access status: hybrid
Estimated APC paid: $3,255
Funders: Eli Lilly and Company, AstraZeneca, GlaxoSmithKline, American Psychiatric Institute for Research and Education, European Commission, Deutsche Forschungsgemeinschaft, GlaxoSmithKline foundation, Fondation pour la Recherche Médicale, Technische Universität Dresden, Shire, RWTH Aachen University
Awards: G2897770627, G3126823965, G585704812, G88412094
OpenAlex ID: W4220677780
